Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why Shares of Savara Jumped on Tuesday Motley Fool - Tue May 16, 2023

The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.

SVRA : 4.27 (+1.18%)
Savara Announces New Employment Inducement Grant Business Wire - Fri May 5, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

SVRA : 4.27 (+1.18%)
Savara Announces New Employment Inducement Grant Business Wire - Fri Mar 31, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

SVRA : 4.27 (+1.18%)
Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update Business Wire - Thu Mar 30, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2022 and...

SVRA : 4.27 (+1.18%)
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Mon Mar 6, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare...

SVRA : 4.27 (+1.18%)
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire - Tue Feb 28, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.

SVRA : 4.27 (+1.18%)
Savara Announces New Leadership Appointments Business Wire - Tue Feb 14, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointments of two pharmaceutical industry veterans to its executive leadership...

SVRA : 4.27 (+1.18%)
Why Shares of Savara Soared This Week Motley Fool - Fri Jan 27, 2023

The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.

SVRA : 4.27 (+1.18%)
Savara Announces New Employment Inducement Grant Business Wire - Fri Jan 20, 2023

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

SVRA : 4.27 (+1.18%)
Savara Announces New Employment Inducement Grant Business Wire - Tue Nov 22, 2022

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of an employee inducement award.

SVRA : 4.27 (+1.18%)

Barchart Exclusives

3 AI Stocks to Buy Instead of Super Micro Computer Barchart - Sat Aug 31, 7:30AM CDT
Following a significant drop in Super Micro Computer's stock due to a delayed 10-K filing and accounting concerns, investors are exploring alternative AI infrastructure stocks like Dell, Arista Networks, and Pure Storage, which offer strong growth prospects in the rapidly expanding AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot